Curis obtains conditional approval of Erivedge in EU
The approval, which is applicable to all 28 EU member states, has triggered $6m milestone payment to Curis from Genentech, a member of the Roche Group. Curis is
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.
Meeting the standards of child-resistant packaging, the new Kush containers are constructed with medical grade plastic, utilizing FDA approved material, and are BPA-free. Kush Bottles chief operating officer
The collaboration is focused on the development of a new generation of steroids and steroids related pharmaceuticals for rapid subcutaneous absorption. PharmaNova’s NovaSperse nanoparticle technology will be leveraged